Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease

15 de junho de 2026 atualizado por: Xuanwu Hospital, Beijing

Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease

The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:

Does adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?

Is the treatment combination safe for participants?

Researchers will compare two groups:

Group 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.

Group 2 (Control): Standard treatment alone.

Participants in this study will:

Be adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).

Be randomly assigned to one of the two treatment groups.

Take their assigned treatment for 6 months.

Attend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

300

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  1. Aged 18 to 70 years (inclusive), male or female.
  2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines.
  3. Glycated hemoglobin (HbA1c) < 12%, with recent fasting blood glucose < 7.0 mmol/L OR postprandial blood glucose < 10.0 mmol/L, and triglycerides < 1.7 mmol/L.
  4. Diagnosed with LEAD, meeting the following criteria:

    Rutherford Classification 2, 3, or 4.

    Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI > 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%.

    Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA.

  5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing "Practical Diagnostic Criteria for Blood Stasis Syndrome" and "Integrated Chinese and Western Medicine Peripheral Vascular Disease"):

    Main Symptom: Lower limb weakness, or feeling of heaviness/discomfort after prolonged walking.

    Secondary Symptoms: Shortness of breath/lassitude in speaking; dry mouth with desire to drink; scaly skin.

    Tongue & Pulse: Tongue with teeth marks, pale-purple with petechiae/ecchymosis; thin and choppy pulse.

    (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)

  6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits.

Exclusion Criteria:

  1. Known bleeding disorders or history of intracranial hemorrhage.
  2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors).
  3. Presence of active infection.
  4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval).
  5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy.
  6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR < 30 mL/min/1.73m²).
  7. History of malignancy (except cured basal cell carcinoma).
  8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome.
  9. Planned lower limb revascularization or amputation.
  10. Concurrent or planned use of medicinal products containing Veratrum species.
  11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception.
  12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin).
  13. Patients with psychiatric disorders or judged to be uncooperative.
  14. Currently participating in another drug clinical trial or using therapies with similar purported effects.
  15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Standard Therapy and Hua Yu Wan Capsule

1. Standard Baseline Medication: Hua Yu Wan Capsule: 5g, taken orally two times daily. Treatment Duration: The combined regimen is administered continuously for 6 months (divided into four 6-week cycles).

2. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments without receiving the study drug.

A modern preparation of the classic Traditional Chinese Medicine formula Bu Yang Huanwu Decoction. Each capsule contains 0.2g of the herbal extract.

Dosage and Route: 2 capsules, taken orally three times daily.

Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 12 months.
Comparador Ativo: Standard Therapy Alone
  1. Standard Baseline Medication:

    Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 6 months.

  2. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments.
Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 12 months.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence of new-onset ischemic rest pain or foot ulcer at 12 months of treatment.
Prazo: From enrollment to the end of treatment at 12 months

Ischemic Rest Pain: Persistent pain in the toes/forefoot at rest, typically nocturnal, worsened by elevation, relieved by dependency, often with pallor/coldness.

Foot Ulcer: Ischemic skin breakdown/tissue necrosis in pressure areas (toes, heel, sole), with well-defined edges, dry/necrotic base, poor perfusion, and absence of significant inflammation.

Assessment Method: Clinical evaluation by investigator at each scheduled visit. Confirmed by physical examination and documented photographically if applicable.

From enrollment to the end of treatment at 12 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Number of participants with investigator-confirmed new-onset ischemic rest pain or clinically confirmed ischemic foot ulcer at 12 months
Prazo: From enrollment to the end of treatment at 12 months
Composite primary outcome defined as the number of participants who develop either: (1) new-onset ischemic rest pain confirmed by investigator clinical assessment, or (2) ischemic foot ulcer confirmed by physical examination with photographic documentation when applicable, by Month 12.
From enrollment to the end of treatment at 12 months
Number of participants with major adverse cardiovascular and cerebrovascular events (MACCE)
Prazo: From enrollment to the end of treatment at 12 months
MACCE is defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
From enrollment to the end of treatment at 12 months
Number of participants hospitalized during the study
Prazo: From enrollment to the end of treatment at 12 months
Number of participants who require inpatient hospitalization for any cause during the study period, as confirmed by hospital admission records or investigator documentation. Repeated hospitalizations in the same participant will be counted once unless otherwise specified in the statistical analysis plan.
From enrollment to the end of treatment at 12 months
Number of participants who die during the study
Prazo: From enrollment to the end of treatment at 12 months
Number of participants who die from any cause during the study period, as confirmed by medical records, death certificates, hospital documentation, or investigator follow-up. Each participant will be counted once.
From enrollment to the end of treatment at 12 months
Change in ankle-brachial index(ABI) from baseline
Prazo: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in ankle-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in toe-brachial index (TBI) from baseline
Prazo: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in toe-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in intermittent claudication distance from baseline
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in intermittent claudication distance from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Rate of clinically driven lower-extremity arterial revascularization after treatment
Prazo: From enrollment to the end of treatment at 12 months
Rate of clinically driven lower-extremity arterial revascularization after treatment, including endovascular or open surgical revascularization: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months
Change in Vascular Quality of Life Questionnaire-6 score from baseline
Prazo: From enrollment to the end of treatment at 12 months
Change in Vascular Quality of Life Questionnaire-6 score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months
Change in Traditional Chinese Medicine syndrome score from baseline
Prazo: From enrollment to the end of treatment at 12 months
Change in Traditional Chinese Medicine syndrome score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Number of participants with clinically significant bleeding events
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with bleeding events during the study. Unit of Measure: Participants
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal physical examination findings
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal findings on physical examination.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal hematology test results
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in hematology parameters, including white blood cell count, red blood cell count, hemoglobin, and platelet count.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal urinalysis results
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in urinalysis parameters, including urine white blood cells, urine red blood cells, urine glucose, and urine protein.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal liver function test results
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in liver function parameters, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, and gamma-glutamyl transferase.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal renal function test results
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in renal function parameters, including blood urea nitrogen or urea, and serum creatinine.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal coagulation test results
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in coagulation function parameters, including thrombin time, prothrombin time, activated partial thromboplastin time, international normalized ratio, and fibrinogen.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Body Temperature From Baseline
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in body temperature from baseline at each scheduled assessment. Unit of Measure: Degrees Celsius
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Pulse Rate From Baseline
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in pulse rate from baseline at each scheduled assessment. Unit of Measure: Beats per minute
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Respiratory Rate From Baseline
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in respiratory rate from baseline at each scheduled assessment. Unit of Measure: Breaths per minute
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Systolic Blood Pressure From Baseline
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in systolic blood pressure from baseline at each scheduled assessment. Unit of Measure: mmHg
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Diastolic Blood Pressure From Baseline
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in diastolic blood pressure from baseline at each scheduled assessment. Unit of Measure: mmHg
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal 12-lead electrocardiogram findings
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Measure Description: Number of participants with clinically significant abnormal findings on 12-lead electrocardiogram, as assessed by the investigator.

Unit of Measure: Participants

Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with positive pregnancy test results
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of female participants of childbearing potential with positive pregnancy test results during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Allergic Reactions
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with allergic reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Gastrointestinal Adverse Reactions
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with gastrointestinal adverse reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Nervous System Adverse Reactions
Prazo: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with nervous system adverse reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de junho de 2026

Conclusão Primária (Estimado)

1 de fevereiro de 2028

Conclusão do estudo (Estimado)

1 de janeiro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

11 de fevereiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de junho de 2026

Primeira postagem (Real)

22 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever